Crystalline form, pharmaceutical formulation, use of a crystalline form, use of a substance, methods for the treatment or prophylaxis of, conditions associated with reduced insulin sensitivity, and delipidemia, type 2 diabetes mellitus, hyperglycemia, hyperinsulinemia, hypertension and / or abdominal obesity, and, process for the preparation of a crystalline form of a compound of formula i

摘要

"CRYSTALLINE FORM, PHARMACEUTICAL FORMULATION, USE OF A CRYSTALLINE FORM, USE OF A SUBSTANCE, METHODS FOR TREATMENT OR PROPHYLAXIS OF, CONDITIONS ASSOCIATED WITH REDUCED INSULIN SENSITIVITY, AND DELIPIDEMIA, HYPERTEMINUM HYPERTEMINUM, AND / OR ABDOMINAL OBESITY, AND, PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF A COMPOUND OF FORMULA I ". The present invention relates to a new crystalline form of the (S) -2-ethoxy-3- [4- (2- (4-methanesulfonyloxyphenyl) ethoxy) phenyl] propanoic acid compound, shown by formula (1) or a pharmaceutically acceptable salt and solvates thereof. The invention also relates to methods of treating one or more metabolic disease conditions, particularly those associated with Insulin Resistance Syndrome, and the use of a crystalline form of the compound, or a pharmaceutically acceptable salt thereof, or a its solvate, in the manufacture of a medicine for use in one or more of the aforementioned conditions. The invention further relates to pharmaceutical compositions containing a crystalline form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient, as well as processes for the manufacture of a crystalline form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.